XML 77 R66.htm IDEA: XBRL DOCUMENT
v3.23.1

Commitments and Contingencies (Details) |  |  |  |  |  |  |  |  |  |  |  |  | 3 Months Ended | 12 Months Ended | 16 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Mar. 08, 2023 USD ($) | Apr. 19, 2022 case | Mar. 11, 2022 stockholder | Mar. 07, 2022 stockholder | Mar. 05, 2022 case | Feb. 28, 2022 case | Dec. 24, 2021 USD ($) case | Sep. 11, 2020 | Oct. 02, 2019 | Mar. 24, 2015 patent | Feb. 15, 2015 | Feb. 11, 2015 patent | Mar. 31, 2023 lawsuit | Dec. 31, 2021 case | Sep. 30, 2017 patent
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of lawsuits dismissed |  |  |  |  |  |  |  |  |  |  |  |  |  | 13 |
Claims settled |  |  |  |  |  |  | 27 |  |  |  |  |  |  |  |
Xtampza ER Litigation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents listed in FDA Orange Book | patent |  |  |  |  |  |  |  |  |  |  |  | 11 |  |  |
Stay period before FDA can issue a final approval unless it is terminated |  |  |  |  |  |  |  |  |  | 30 months | 30 months |  |  |  |
Number of patents allegedly infringed | patent |  |  |  |  |  |  |  |  |  | 3 |  | 5 |  |  | 2
Number of lawsuits filed | patent |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2
PTAB duration for issuing decision |  |  |  |  |  |  |  |  | 1 year |  |  |  |  |  |
Statutory period of proceedings |  |  |  |  |  |  |  | 18 months |  |  |  |  |  |  |
Xtampza ER Litigation | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
PTAB extended duration for issuing decision |  |  |  |  |  |  |  |  | 6 months |  |  |  |  |  |
Xtampza ER Litigation, District of Massachusetts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stay period before FDA can issue a final approval unless it is terminated |  |  |  |  |  |  |  |  |  | 30 months |  |  |  |  |
Number of patents allegedly infringed | patent |  |  |  |  |  |  |  |  |  | 3 |  |  |  |  |
Opioid Litigation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of lawsuits filed | lawsuit |  |  |  |  |  |  |  |  |  |  |  |  | 6 |  |
Number of lawsuits dismissed |  | 8 |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement, amount awarded to other party | $ |  |  |  |  |  |  | $ 2,750,000 |  |  |  |  |  |  |  |
Claims settled |  |  |  |  |  |  | 27 |  |  |  |  |  |  |  |
Opioid Litigation, Massachusetts state court |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of lawsuits by municipalities | lawsuit |  |  |  |  |  |  |  |  |  |  |  |  | 13 |  |
Multi-District Litigation (MDL) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of lawsuits filed |  |  |  |  |  |  |  |  |  |  |  |  |  | 21 |
Number of lawsuits dismissed |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |
Claims settled |  |  |  |  |  |  | 8 |  |  |  |  |  |  |  |
State court |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Claims settled |  |  |  |  |  |  | 19 |  |  |  |  |  |  |  |
BDSI Acquisition Litigation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of additional cases filed |  |  |  |  | 2 | 2 |  |  |  |  |  |  |  |  |
Number of demand letters received from purported stockholders | stockholder |  |  | 4 | 3 |  |  |  |  |  |  |  |  |  |  |
Aquestive Therapeutics, Inc Litigation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement, amount awarded to other party | $ | $ 8,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Initial duration for issuing its decision by PTAB. + References No definition available. + Details
Name: | coll_DurationForDecisionIssue
Namespace Prefix: | coll_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Extended period for issuing its decision by PTAB. + References No definition available. + Details
Name: | coll_ExtendedDurationForDecisionIssue
Namespace Prefix: | coll_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of additional cases filed. + References No definition available. + Details
Name: | coll_LossContingencyNumberOfAdditionalCasesFiled
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of demand letters received from purported stockholders. + References No definition available. + Details
Name: | coll_LossContingencyNumberOfDemandLettersReceivedFromPurportedStockholders
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the stay period before the Federal Drug Administration (FDA) can issue final approval unless the stay is terminated. + References No definition available. + Details
Name: | coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected
Namespace Prefix: | coll_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of lawsuits by Municipalities. + References No definition available. + Details
Name: | coll_NumberOfLawsuitsByMunicipalities
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of patents listed in FDA Orange Book + References No definition available. + Details
Name: | coll_NumberOfPatentsListedInFdaOrangeBook
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Statutory period of proceedings. + References No definition available. + Details
Name: | coll_StatutoryPeriodOfProceedings
Namespace Prefix: | coll_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount awarded to other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of claims dismissed. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 + Details
Name: | us-gaap_LossContingencyClaimsDismissedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of claims settled. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 + Details
Name: | us-gaap_LossContingencyClaimsSettledNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The total number of new claims filed pertaining to a loss contingency during the period. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 + Details
Name: | us-gaap_LossContingencyNewClaimsFiledNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of another entity's patents that the entity has allegedly infringed. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 + Details
Name: | us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_OpioidLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_OpioidLitigationAtMassachusettsStateCourtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_MultiDistrictLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_OpioidLitigationStateCourtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_BdsiAcquisitionLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_AquestiveTherapeuticsIncLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |